Residual T1 plus CIS after re-resection: BCG or cystectomy?
A 62-year-old man has a 3 cm high-grade papillary urothelial carcinoma with carcinoma in situ on a background of two previous recurrences, treated 8 months ago with complete transurethral resection and a single immediate mitomycin instillation. Restaging resection 4 weeks later shows residual high-grade T1 disease with carcinoma in situ; muscle is present in the specimen, and there is no lymphovascular invasion. Staging CT urography shows no upper tract disease and no lymphadenopathy; creatinine 88 µmol/L. He has well-controlled hypertension, exercises regularly and runs his own business. He is keen 'not to lose the bladder' but also asks what gives him the best chance of cure. Your department offers maintenance BCG and robot-assisted radical cystectomy with intracorporeal urinary diversion. Cystoscopy at 3 months would be available.
1. How do you classify his risk, and what are the two realistic treatment strategies?
Read the worked answer
This is very high-risk non-muscle-invasive bladder cancer by EAU criteria: high-grade T1 with concomitant carcinoma in situ, multiple recurrences and residual T1 at re-resection. The muscle being present makes the staging adequate, and CT urography has excluded upper tract disease and nodal spread. The risk of progression to muscle-invasive disease is substantial, and this should be discussed explicitly rather than framed as 'just BCG'.
The two realistic strategies are intravesical BCG with induction and maintenance for up to three years, with strict 3-month assessment and early recourse to cystectomy if there is failure, or immediate radical cystectomy with urinary diversion. BCG offers bladder preservation and is recommended for high-risk disease; it reduces recurrence and progression but fails in a significant minority, and a delayed cystectomy after failure may have worse outcomes than early surgery. Early cystectomy gives the best oncological control for a patient who is fit, with excellent survival when nodes are negative, but carries 90-day morbidity in the region of 20–30%, a mortality of about 1–3% in high-volume centres, and a lifelong diversion with metabolic and functional consequences.
A third option, further endoscopic resection alone or intravesical chemotherapy alone, is inadequate for T1 with CIS. The decision should be made in a multidisciplinary meeting and with the patient, explicitly weighing cure and bladder preservation.
2. If he chooses BCG, exactly how do you assess response, and what do you do at each checkpoint?
Read the worked answer
BCG should be given as induction followed by maintenance. Assessment is by cystoscopy with cytology, and biopsy of any suspicious area, at 3 months; the bladder must not be declared clear on cytology alone when there is visible abnormality or persistent positive cytology.
At 3 months: if there is persistent high-grade T1 or carcinoma in situ, this is early BCG failure and I would recommend radical cystectomy rather than further BCG. If the bladder is clear, continue maintenance with regular cystoscopy and cytology. If there is recurrence of low-grade non-invasive disease, it can usually be managed by resection and continued BCG. At 6 months, persistent carcinoma in situ or high-grade disease after adequate BCG defines BCG-unresponsive disease, and cystectomy is the standard recommendation; further BCG has a low chance of durable response and risks delaying curative surgery. A second induction course may be considered in selected patients with persistent CIS at 3 months who are unwilling to undergo cystectomy, with a clear understanding of the trade-off.
Throughout, he needs to be told that bladder preservation depends on reliable follow-up, and that a positive cytology with a normal-looking bladder requires upper tract and prostatic urethral assessment, including random biopsies, before continuing bladder-sparing treatment.
3. What findings would make you recommend immediate cystectomy rather than a trial of BCG?
Read the worked answer
Several features would shift the balance towards immediate cystectomy. Disease that cannot be completely resected endoscopically, or a re-resection showing deep lamina propria invasion with lymphovascular invasion, makes bladder preservation less safe. Prostatic urethral or ureteric involvement, hydronephrosis, or a palpable mass suggest more advanced or bulky disease and warrant restaging, often including examination under anaesthesia. A very large or multifocal tumour burden, especially with carcinoma in situ extending into the prostatic urethra, is difficult to control with BCG. Previous recurrence within a short interval, as here, adds to the risk.
Patient factors matter equally: fitness for cystectomy is time-limited, and delay through a failed BCG course may lose the window for a curative operation. A patient who cannot or will not attend rigorous surveillance, or who has poor bladder function or capacity, is better served by early surgery. Conversely, a patient with severe comorbidity and limited life expectancy may reasonably choose BCG despite higher risk of progression.
The consultation should present the trade-offs plainly: BCG preserves the bladder but carries a meaningful risk of failure and progression, while cystectomy offers the best chance of cure at the cost of major surgery and a changed body image and function. Document his values and the MDT recommendation.